Porokeratosis encompass a group of acquired and familial, preneoplastic, keratinization disorders, clinically characterized by atrophic macules or patches with a peripheral keratotic rim, the cornoid lamella. Genetic background is recognized as crucial in its pathophysiology, while immunosuppression and ultraviolet radiation represent triggering factors. We report the case of a woman who developed disseminate superficial actinic porokeratosis following the intake of hydroxyurea for a polycythaemia vera. Clinical, dermoscopic and histopathology data are showed, and the role of drug as a second-hit mutation trigger is discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ajd.13943 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Daylight Photodynamic Therapy: At-Home Delivery.
J Clin Med
December 2024
School of Medicine, University of Dundee, Dundee DD1 4HN, UK.
This pilot study evaluated the design, usability, and practicality of the dPDT@home kit for treating actinic keratoses (AKs) on the face and scalp. The kit allowed patients to manage their treatment at home, reducing hospital visits and utilizing natural sunlight. While patients were very willing to use the kit again, further studies are required to evaluate outcomes and ascertain the need for additional improvements and support.
View Article and Find Full Text PDFStevens-Johnson induced by imiquimod 5% cream: a case report.
Dermatol Reports
November 2024
Department of Dermatology, Dipartimento della Salute (DiSSal), University of Genoa; IRCCS, Ospedale Policlinico San Martino, Genoa, Italy.
Imiquimod 5% cream is an approved treatment for actinic keratoses, superficial basal cell carcinomas, and anogenital warts. Severe systemic side effects associated with imiquimod 5% cream are rare, although a few cases of erythema multiforme and Stevens-Johnson syndrome have been described. We present a case of Stevens-Johnson syndrome associated with topical treatment with imiquimod of two superficial basal cell carcinomas.
View Article and Find Full Text PDFAnalysis of tumoral, stromal and glycolitic markers in the response basal cell carcinoma and Bowen disease to photodynamic therapy in real life.
Photodiagnosis Photodyn Ther
December 2024
Department of Dermatology, Miguel Servet University Hospital, University of Zaragoza, IIS Aragón. Zaragoza, Spain.
Background: Photodynamic therapy (PDT) is a widely-used non-surgical treatment for non-melanoma skin cancers, including basal cell carcinoma (BCC), actinic keratoses (AK), and Bowen's disease (BD). PDT has high success rates, but various factors, can influence treatment response. This study investigates the clinical, histological, and molecular factors that affect the efficacy of methyl aminolevulinate PDT (MAL-PDT) for BCC and BD.
View Article and Find Full Text PDFDisseminated Superficial Actinic Porokeratosis Treated with Topical Simvastatin: Evaluation of Therapeutic Response with Dermoscopy.
Dermatol Pract Concept
October 2024
Dermatology Department, Hospital Provincial del Centenario de Rosario, Universidad Nacional de Rosario, Rosario, Argentina.
Disseminated Superficial Non-actinic Porokeratosis: A Consequence of Post-traumatic Immunosuppression.
Cureus
November 2024
Oncologic Dermatology, Elias Emergency University Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU.
Disseminated superficial porokeratosis (DSP) is a very uncommon dermatologic condition of unknown etiology, characterized by the clonal proliferation of atypical keratinocytes associated with aberrant keratinocyte differentiation. These lead to the development of the specific cornoid lamella that separates atypical from normal keratinocytes. DSP is most frequently encountered in immunosuppressed patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!